Rafael Peláez Lamamie de Claira Arroyo-rekin lankidetzan egindako argitalpenak (9)

2024

  1. Experimental structure based drug design (SBDD) applications for anti-leishmanial drugs: A paradigm shift?

    Medicinal Research Reviews, Vol. 44, Núm. 3, pp. 1055-1120

2023

  1. Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

  2. Novel Tetrazole Derivatives Targeting Tubulin Endowed with Antiproliferative Activity against Glioblastoma Cells

    International Journal of Molecular Sciences, Vol. 24, Núm. 13

  3. Novel amino analogs of the trimethoxyphenyl ring in potent colchicine site ligands improve solubility by the masked polar group incorporation (MPGI) strategy

    Bioorganic Chemistry, Vol. 131

  4. Nuevos antitumorales y antiparasitarios de naturaleza híbrida para la formación de nanopartículas

    IX Jornadas de investigadoras de Castilla y León

  5. Potent and Selective Benzothiazole-Based Antimitotics with Improved Water Solubility: Design, Synthesis, and Evaluation as Novel Anticancer Agents

    Pharmaceutics, Vol. 15, Núm. 6

2021

  1. Anticancer properties of indole derivatives as IsoCombretastatin A-4 analogues

    European Journal of Medicinal Chemistry, Vol. 223

  2. Application of ensemble pharmacophore-based virtual screening to the discovery of novel antimitotic tubulin inhibitors

    Computational and Structural Biotechnology Journal, Vol. 19, pp. 4360-4372

2019

  1. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors

    Molecules (Basel, Switzerland), Vol. 24, Núm. 23